Literature DB >> 26448447

Epidemiology and Diagnosis of Myopic Choroidal Neovascularization in Asia.

Nicole Shu-Wen Chan1, Kelvin Teo, Chui Ming Gemmy Cheung.   

Abstract

BACKGROUND: This article aims to review recent advances in the understanding of epidemiology and risk factors for the development of myopic choroidal neovascularization (CNV) and highlight the diagnostic features of myopic CNV and signs seen on the noninvasive optical coherence tomography technology, which may be particularly useful for the purpose of screening. Choroidal neovascularization is a sight-threatening complication of pathologic myopia. Because myopic CNV frequently affects individuals during their working life, its socioeconomic impact is significant, especially in Asian countries where the prevalence of pathologic myopia is high. EPIDEMIOLOGY: Pathological myopia is the most common cause of CNV in patients less than 50 years old, and it is estimated that 5.2% to 11.3% of individuals with pathologic myopia develop myopic CNV. RISK FACTORS: The risk of developing myopic CNV increases with the severity of myopia and macular changes, such as diffuse atrophy, lacquer cracks, and patchy atrophy, which progress to myopic CNV in a significant proportion. Vascular endothelial growth factor (VEGF) may contribute to the development of myopic CNV. NATURAL COURSE AND PROGNOSIS: Untreated myopic CNV carries a poor visual prognosis, with an estimated 89% of the patients having marked visual impairment within 5 years of onset. TREATMENT: Anti-VEGF therapy is efficacious in treating myopic CNV. Although this significantly improves the short-term prognosis of myopic CNV, the long-term visual loss due to the sequela of myopic CNV including macular atrophy and scarring remains.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26448447     DOI: 10.1097/ICL.0000000000000201

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  12 in total

1.  Evaluation of 10 AMD Associated Polymorphisms as a Cause of Choroidal Neovascularization in Highly Myopic Eyes.

Authors:  Alvaro Velazquez-Villoria; Sergio Recalde; Jaouad Anter; Jaione Bezunartea; Maria Hernandez-Sanchez; Laura García-García; Elena Alonso; Jose María Ruiz-Moreno; Javier Araiz-Iribarren; Patricia Fernandez-Robredo; Alfredo García-Layana
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

2.  Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age.

Authors:  Dimitrios Karagiannis; Georgios A Kontadakis; Konstantinos Kaprinis; Athanassios Giarmoukakis; Ilias Georgalas; Efstratios A Parikakis; Miltiadis K Tsilimbaris
Journal:  Clin Ophthalmol       Date:  2017-06-22

3.  Macular assessment of preoperative optical coherence tomography in ageing Chinese undergoing routine cataract surgery.

Authors:  Xiaoli Huang; Zhengwei Zhang; Jie Wang; Xiaomei Meng; Tiantian Chen; Zhifeng Wu
Journal:  Sci Rep       Date:  2018-03-23       Impact factor: 4.379

4.  VALIDATION OF THE RECENTLY DEVELOPED ATN CLASSIFICATION AND GRADING SYSTEM FOR MYOPIC MACULOPATHY.

Authors:  Jorge Ruiz-Medrano; Ignacio Flores-Moreno; Kyoko Ohno-Matsui; Chui Ming Gemmy Cheung; Rufino Silva; José M Ruiz-Moreno
Journal:  Retina       Date:  2020-11       Impact factor: 3.975

5.  Shaping Eyeballs by Scleral Collagen Cross-Linking: A Hypothesis for Myopia Treatment.

Authors:  Mengmeng Wang; Christine Carole C Corpuz; Fengju Zhang
Journal:  Front Med (Lausanne)       Date:  2021-07-02

6.  Minimally Invasive Repetitive UVA Irradiation along with Riboflavin Treatment Increased the Strength of Sclera Collagen Cross-Linking.

Authors:  Bo Xiao; Yanhua Chu; Hongyan Wang; Quanhong Han
Journal:  J Ophthalmol       Date:  2017-12-17       Impact factor: 1.909

7.  Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.

Authors:  Jin Jing; Shen Yinchen; Chen Xia; Wang Jing; Chen Chong; Xu Xun; Huang Hengye; Liu Kun
Journal:  BMC Ophthalmol       Date:  2018-07-24       Impact factor: 2.209

8.  Pathological myopia-induced antioxidative proteins in the vitreous humor.

Authors:  Qiaoling Wei; Ting Zhang; Jiawen Fan; Rui Jiang; Qing Chang; Jin Hong; Gezhi Xu
Journal:  Ann Transl Med       Date:  2020-03

9.  Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study.

Authors:  Robin D Hamilton; Andreas Clemens; Angelo Maria Minnella; Timothy Y Y Lai; Hong Dai; Taiji Sakamoto; Chui Ming Gemmy Cheung; Nor Fariza Ngah; Cornelia Dunger-Baldauf; Frank G Holz
Journal:  PLoS One       Date:  2020-01-21       Impact factor: 3.240

10.  Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization.

Authors:  Devangna Bhatia; Alexander Mehta; Joanna DaCosta; Oonagh Crothers; James Stephen Talks
Journal:  Clin Ophthalmol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.